Next Generation Sequencing (NGS) in Relapsed/Refractory HPV Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Reveals Diverse Genomic Alterations and Potential Targets of Therapy

Najjar Esmat1*, Ohad Hilly1, Aviram Mizrachi1, Dror Limon2, Shvero Jacob1, Addie Dvir3, Lior Soussan Gutman1 and Aron Popovtzer2

1Departments of Otolaryngology, Head and Neck Surgery, Rabin Medical Center, Israel
2Oncology, Rabin Medical Center, Petach Tikva, affiliated with Sackler Faculty of Medicine, Tel Aviv
3Oncotest-Teva, Teva Pharmaceuticals Industries, Petach Tikva, Israel

*Corresponding author: Esmat Najjar, Department of ENT, Head and Neck Surgery, Rabin Medical Center, Beilinson Campus, 39 Jabotinski St, Petach Tikva, Israel 49100

ARTICLE INFO

Introduction

Managing advanced, recurrent, and metastatic head and neck cancer is challenging. Treatment options are limited, and prognosis is poor even when aggressive combinations of radiotherapy and chemotherapy are administered [1]. The addition of biological agents such as cetuximab prolongs survival by only a few months [2]. The inability to cure or even, in many cases, to slow the progression of the tumor has prompted investigators to search for potential new targets of systemic therapy. The introduction of next-generation sequencing has reduced the cost and processing time of genetic profiling, making it feasible in clinical scenarios [3,4]. However, although a myriad of genetic alterations can be detected with the available techniques, their translation into a benefit for patients with cancer presents a major hurdle [5]. The aim of this study was to explore genetic alterations in advanced, recurrent head cancer.
and neck squamous cell carcinoma (HNSCC) using a commercially available next-generation sequencing platform. The literature was reviewed to evaluate the clinical implications of the findings.

**Materials and Methods**

**Patients**

The study group consisted of 8 patients with advanced recurrent HNSCC treated at a tertiary cancer center from 2012 to 2013. Their clinical characteristics are shown in Table 1. There were 4 men and 4 women of mean age 51.5 years at diagnosis (range 26-68 years). Tumor sites included the tongue (3 patients), skin/parotid (2 patients), and larynx, nasopharynx, and tonsil (1 patient each). All tumors were negatively immunostained for p16 and were considered HPV negative. Five patients had advanced disease at presentation. Seven patients were surgically treated with curative intent, followed by radiotherapy and platinum-based chemotherapy. One patient (with nasopharyngeal cancer) underwent radiotherapy and chemotherapy only. The mean number of treatment lines before submission of the tumors for next-generation profiling was 3.4. Five patients (63%) died of their disease; mean time from next-generation sequencing to death was 11 months. The other three patients are alive with persistent disease after follow-up of 1, 10.5, and 27 months. Treatment decision-making was influenced by the sequencing results in one patient, as detailed below.

**Table 1:** Clinical characteristics of 8 patients prior to next-generation sequencing.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Age at diagnosis (years)</th>
<th>Sex</th>
<th>Primary tumor site</th>
<th>pTNM at diagnosis</th>
<th>Treatment lines prior to next-generation sequencing</th>
<th>Time to relapse (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>57</td>
<td>Female</td>
<td>Tongue</td>
<td>T2 N2B M0</td>
<td>1st: CRes with close margin+CIS+Rx66Gy</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2nd: CIS 5fu Erbitux</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3rd: Afatanib</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>45</td>
<td>Male</td>
<td>Tonsil</td>
<td>T2 N2 M0</td>
<td>1st: CRes CIS Rx66Gy</td>
<td>48</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2nd: Erbitux + Rx66Gy</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3rd: Carbo TAX Rx66Gy</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4th: Xeloda</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5th: Methotrexate</td>
<td>6</td>
</tr>
<tr>
<td>3</td>
<td>34</td>
<td>Female</td>
<td>Tongue</td>
<td>T1 N0 M0</td>
<td>1st: CRes</td>
<td>132</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2nd: CRes</td>
<td>168</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3rd: ICRes CIS Rx66Gy</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4th: CIS 5FU Erbitux</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5th: TAX</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>64</td>
<td>Male</td>
<td>Nasopharynx</td>
<td>T4 N0 M0</td>
<td>1st: CIS+Rx70Gy</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2nd: Carbo TAX</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3rd: Gemcitabine</td>
<td>12</td>
</tr>
<tr>
<td>5</td>
<td>26</td>
<td>Male</td>
<td>Tongue</td>
<td>T2 N1 M0</td>
<td>1st: CRes CIS Rx66Gy</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2nd: CIS TAX 5FU</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3rd: Erbitux Rx70Gy</td>
<td>5</td>
</tr>
<tr>
<td>6</td>
<td>62</td>
<td>Female</td>
<td>Skin-parotid</td>
<td>T2 N2C M0</td>
<td>1st: ICRes CIS Rx70Gy</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2nd: Erbitux</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3rd: TAX</td>
<td>3</td>
</tr>
<tr>
<td>7</td>
<td>56</td>
<td>Male</td>
<td>Larynx</td>
<td>T1 N0 M0</td>
<td>1st: R66Gy</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2nd: CRes CIS Rx70Gy</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3rd: Erbitux Rx60Gy</td>
<td>6</td>
</tr>
<tr>
<td>8</td>
<td>68</td>
<td>Female</td>
<td>Skin-parotid</td>
<td>T1N0M0</td>
<td>1st: CRes</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2nd: ICRes CIS Rx66Gy</td>
<td>12</td>
</tr>
</tbody>
</table>

**Next Generation Sequencing**

Next-generation sequencing was performed with the Clinical Laboratory Improvement Amendments (CLIA)-approved FoundationOne™ platform (Foundation Medicine, Cambridge, MA, USA). FoundationOne is a targeted assay designed for use in routine formalin-fixed paraffin-embedded cancer specimens as small as 40μm. It simultaneously sequences the entire coding sequence of 236 cancer-related genes (3769 exons) plus 48 introns from 20 genes that are often rearranged or altered in cancer, to an average depth coverage of >250X. The assay detects all classes of genomic alterations: base substitutions, insertions and deletions, copy number alterations and rearrangements. A full list of sequenced cancer-related genes is available online at the Foundation Medicine.
Results

Next-generation sequencing yielded 31 alterations in 19 genes, with a mean alteration/tumor ratio of 3.9 (range, 1-8 alterations per tumor). Two genes were predominantly involved: TP53 (10 mutations in 6 tumors) and CDKN2A (5 mutations in 5 tumors). One patient had a mutation only in TP53. There was one alteration in each of the following genes: CDKN2B, NOTCH1, EGFR, APC, CCND1, ARID1A, ARID2, SRC, FBXW7, SMARCA4, BRAF, ATM, MLH1, GRIN2A, ASXL1, MLL2, and NOTCH2. Three patients had mutations associated with FDA-approved treatments. In the first, genetic profiling identified EGFR amplification in a chest wall metastasis of a tongue carcinoma, along with mutations in APC-I1307K. Cetuximab has been approved for use in patients with HNSCC associated with EGFR amplification. However, it had already been administered according to standard protocol for 3 months prior to genetic analysis, with no response.

The second patient had a mutation in FBXW7-R465C and treatment with mTOR inhibitors such as everolimus and temsirolimus was suggested. These drugs have been FDA-approved for kidney, breast, and pancreatic cancers and reportedly yielded good results in 3 of 5 patients with HNSCC and either PIK3CA mutations or PTEN loss [6]. A combination of rapamycin (sirolimus) and vorinostat, an HDAC inhibitor that was suggested based on an additional alteration in the SMARCA4 gene, was administered. PET-CT scan performed two months after treatment initiation revealed progressive disease in the neck and a new mediastinal lesion, and treatment was stopped. The third patient had metastatic cutaneous SCC. Next-generation sequencing of a parotid metastasis found a mutation in BRAF (K601E) and treatment with BRAF-inhibitor (vemurafenib) was considered. This treatment was avoided based on a history of cutaneous SCC and a reported increased risk for cutaneous SCC in melanoma patients treated with this drug [7]. On the basis of the FoundationOne assay thorough literature search, clinical trials were suggested in all cases based on their relevancy to 21 gene alterations (Table 2).

Table 2: Genetic alterations detected by next-generation sequencing.

<table>
<thead>
<tr>
<th>Genes</th>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
<th>Patient 4</th>
<th>Patient 5</th>
<th>Patient 6</th>
<th>Patient 7</th>
<th>Patient 8</th>
<th>Suggested treatment alteration-associated</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment options</strong></td>
<td>Cetuximab</td>
<td>mTOR inhibitor</td>
<td>CDK4/6 inhibitors</td>
<td>Clinical trial</td>
<td>Clinical trial</td>
<td>Clinical trial</td>
<td>Clinical trial</td>
<td>Clinical trial</td>
<td>Clinical trial</td>
</tr>
<tr>
<td><strong>TP53</strong></td>
<td>TP53</td>
<td>C135R</td>
<td>P142fs*5</td>
<td>V216M</td>
<td>E286K, G245D, P151S, W146*</td>
<td>A86fs*55</td>
<td>G245S, H179Y</td>
<td>Clinical trial</td>
<td></td>
</tr>
<tr>
<td><strong>CDKN2A</strong></td>
<td>Loss</td>
<td>R22P</td>
<td>N39K</td>
<td>E119*</td>
<td>P114L</td>
<td>Clinical trial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CDKN2B</strong></td>
<td>Loss</td>
<td>E1665*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Clinical trial</td>
<td></td>
</tr>
<tr>
<td><strong>APC</strong></td>
<td>I1307K</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>powered for other tumor types</td>
<td></td>
</tr>
<tr>
<td><strong>NOTCH1</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Clinical trial</td>
<td></td>
</tr>
<tr>
<td><strong>BRAF</strong></td>
<td></td>
<td></td>
<td></td>
<td>K601E</td>
<td></td>
<td></td>
<td></td>
<td>FDA approved for other tumor types</td>
<td></td>
</tr>
<tr>
<td><strong>CCND1</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Clinical trial</td>
<td></td>
</tr>
<tr>
<td><strong>FBXW7</strong></td>
<td>R465C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FDA approved for other tumor types</td>
<td></td>
</tr>
<tr>
<td><strong>SMARCA4</strong></td>
<td>K1503fs*8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Clinical trial</td>
<td></td>
</tr>
<tr>
<td><strong>EGFR</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Clinical trial</td>
<td></td>
</tr>
<tr>
<td><strong>ATM</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>R2453fs*3</td>
<td></td>
<td></td>
<td>FDA approved for HNSCC</td>
<td></td>
</tr>
<tr>
<td><strong>ARID1A</strong></td>
<td></td>
<td>Q567*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Clinical trial</td>
<td></td>
</tr>
<tr>
<td><strong>ARID2</strong></td>
<td></td>
<td>S1505fs*7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Clinical trial</td>
<td></td>
</tr>
<tr>
<td><strong>SRC</strong></td>
<td></td>
<td>SRC-EXT fusions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Clinical trial</td>
<td></td>
</tr>
<tr>
<td><strong>MLH1</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Splice site 2104-1G&gt;A</td>
<td></td>
<td></td>
<td>Clinical trial</td>
<td></td>
</tr>
<tr>
<td><strong>GRIN2A</strong></td>
<td></td>
<td>S929F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Clinical trial</td>
<td></td>
</tr>
<tr>
<td><strong>ASXLI</strong></td>
<td></td>
<td>G645fs*58</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Clinical trial</td>
<td></td>
</tr>
</tbody>
</table>
well tolerated [16,17]. However, clinical benefit could not be
immunologic response in most patients and was found to be
colorectal [15] and ovarian [16] cancer. It induced a significant
overexpress p53 and has been tested in patients with advanced
tumor from the head and neck as well other sites, with a similar
had a mutation associated with an FDA-approved drug for the
platform. They found actionable alterations in 83%, of which 26%
of genetic alterations in HPV- negative HNSCC was described by
MLL2
NOTCH2
G12Sfs*95
Q1677*

Suggested treatments and clinical trials for actionable gene alterations are detailed in the right column.

Discussion

There is a standard first-line treatment protocol for recurrent,
unresectable, metastatic HNSCC, but no successful second-line
treatment. Next-generation sequencing is a novel tool that can help
clinicians tailor treatment on the basis of gene alterations in tumors.
Using the Foundation One platform, Drilon et al. [8] associated RET-
fusion positivity in non-small cell lung cancer with a good clinical
response to the RET-inhibitor cabozanitib. Similarly, Vaishnavi et al. [9] associated a novel rearrangement in NTRK1-fusion with a
clinical response to crizotinib. Prompted by these studies, we sought to explore the potential and utility of the next-generation
sequencing approach to recurrent HNSCC. In the present study,
profiling of 236 cancer-related genes in tumors from eight patients
with advanced, recurrent, HNSCC yielded 31 genetic alterations (mean, 3.9 alterations per tumor). All tested tumors were affected.

Of the 19 genes with active alterations, only 2, TP53 and CDKN2A, had more than one mutation. Each mutation in both
these genes was unique to the specific tumor. Comparable number of genetic alterations in HPV- negative HNSCC was described by
Zhang P et al. [10] (3.2 per tumor). Genetic alterations associated with FDA- approved therapies were detected in 3 patients, while all other patients had actionable genetic alterations associated with treatments evaluated in clinical trials. Johnson et al. [11] assessed tumor from the head and neck as well other sites, with a similar platform. They found actionable alterations in 83%, of which 26%
had a mutation associated with an FDA-approved drug for the
specific site, and additional 17% had mutations associated with a
drug approved for a different tumor type [11].

Potential Treatments for TP53 Altered Tumors

TP53 was altered in tumors from 6 of the 8 patients. Ten
different mutations were found: 4 in one tumor; 2 in one tumor; and
one mutation in each of the 4 remaining tumors. TP53 mutations
are common in HNSCC as well as other types of cancer. Using the
same sequencing platform, Chung et al. [12] demonstrated over
80% prevalence of TP53 mutations in HPV-negative HNSCC [12].
Similarly, Nichols et al. [13] identified TP53 mutations in 6/6 HNSCC
cell lines [13], and Kandoth et al. [14] in 209/300 HNSCC tumors
(70%) [14]. This rate is similar to our finding (75% of tumors had
TP53 mutations) even though, the vast majority of tumors in that
large series were primary (not recurrences).

There are currently no FDA-approved treatments directed
against mutant p53. However, several treatment strategies have
been evaluated: vaccines, gene therapy, and tyrosine kinases. The
p53 synthetic long peptide (p53-SLP) vaccine targets cells that
overexpress p53 and has been tested in patients with advanced
colorectal [15] and ovarian [16] cancer. It induced a significant
immunologic response in most patients and was found to be
well tolerated [16,17]. However, clinical benefit could not be
demonstrated. Another vaccine, the recombinant modified vaccinia
virus Ankara (MVA) expressing wild-type human p53 (MVA-p53),
was found to induce p53-specific IFN-γ production, degranulation,
cell proliferation, and lysis of p53-overexpressed tumor cells [18].
A phase II trial of two different p53 peptide vaccines showed specific
immune responses with minimal toxicity in patients with ovarian
cancer. The clinical efficacy of these vaccines was not assessed in
this study and no control group was included [19].

A form of gene therapy, rAd-p53, delivers human recombinant
wild-type p53 protein. It has had mixed results in phase II trials in
hepatocellular carcinoma, ovarian cancer, and lung cancer [19-21].
Intraperitoneal injection of rAd-p53 in patients with heavily treated recurrent ovarian cancer decreased CA-125 levels by 50%. However,
it injection to the hepatic artery in patients with hepatocellular
carcinoma and to the bronchial artery in patients with non-
small cell lung cancer yielded no benefit despite a significant
immunologic response. In one study, intratumoral injections of
Ad5CMV-p53, an adenoviral vector delivering wild type pTP53, were
administered to 10 patients with unresectable, chemoradiation-
resistant, esophageal squamous cell carcinoma. The treatment was
found to be safe and well tolerated. Three patients showed absence
do disease on repeated biopsies [22,23].

MK-1775 is a potent and selective Wee-1 tyrosine kinase
inhibitor. It targets CDC2 to inactivate the complex that regulates
the G2 checkpoint. Studies in cell lines and animal models found that
MK-1775 sensitizes p53- deficient tumor cells to chemotherapeutic
agents and radiation; no sensitization was observed in p53 wild-
type tumor cells [24,25].The suggestion that reactivation of p53
may serve as a potential treatment option led to the development of
two alternative small-molecule approaches: stabilization of mutant
p53 to rescue its DNA- binding activity, and inhibition of MDM2 or
MDM4. The results are reviewed by Brown et al. [26] there are no
clinical data currently supporting treatment with these agents.

Potential Treatments for CDKN2A-Altered Tumors

The CDKN2a gene was altered in 5 of our tumors. Studies using
next-generation sequencing reported a CDKN2a mutation in 5/6
HNSCC cell lines [13], and 21% of primary HNSCC tumors in
the largest series published [14].This rate is significantly lower than
ours (63%; Fisher’s exact test, p=0.01), a difference that can suggest
an increased aggressiveness of CDKN2A mutant tumors, or to a
susceptibility of heavily treated tumors to acquire these mutations
after the initial presentation. CDKN2A may be inactivated in HNSCC
through deletion, promoter methylation, or mutation [27-30].
Tumors with loss of the CDKN2A/CDKN2B locus may be sensitive to
CDK4/6 inhibitors, and clinical trials of these agents are currently
underway. In preclinical melanoma studies, the response to CDK4
inhibition correlated with genomic changes that increase CDK4
activity, most notably where the tumor suppressor CDKN2A is

Copyright@ Esmat Najjar | Biomed J Sci & Tech Res | BJSTR. MS.ID.002991.
deleted [31]. Similarly, using glioblastoma cells, researchers found that CDKN2A deletion predicts improved sensitivity to CDK4/6 inhibitors [32]. No CDK4/6 inhibitors are currently approved by the FDA for HNSCC.

FDA-Approved Treatments Suggested by Next-Generation Sequencing

Genetic alterations associated with FDA-approved therapies were detected in 3 patients in the present study (1 mutation each). One had an EGFR amplification, which has been reported in up to 27% of HNSCC cases [33]. EGFR encodes the epidermal growth factor receptor, a receptor tyrosine kinase that passes biochemical messages to the cell and stimulates it to grow and divide. Gene amplification, or mutation, or overexpression of EGFR protein may cause excessive proliferation and tumor formation [34]. Moreover, EGFR amplification and protein expression have been shown to be markers of poor prognosis in HNSCC [35]. Cetuximab is a monoclonal antibody that targets EGFR and was approved for treatment of HNSCC in a phase III trial. However, EGFR amplification did not predict response to this treatment [36]. Other EGFR-targeted therapies, including the tyrosine kinase inhibitors erlotinib, gefitinib, and lapatinib, have been approved by the FDA for use in other cancer types; in phase II trials, lapatinib and gefitinib induced a good response in cases of EGFR overexpression and amplification [37,38].

Currently, EGFR inhibition is well accepted in the treatment of HNSCC whether EGFR is overexpressed or not. Therefore, most patients will be given cetuximab prior to genetic evaluation, and a subsequent finding of EGFR amplification will not influence the treatment. Indeed, our patient had already been treated with cetuximab prior to genetic profiling. The drug was discontinued because of a poor response. FBXW7-R465C alteration is also associated with an FDA-approved drug, though not for HNSCC. It occurs at a mutation hot spot for this gene within the highly conserved WD40 repeat region. Mutations in this region may result in the failure to target substrates for degradation, thereby stabilizing the known oncogenic substrates Cyclin E, Notch1, MYC, Jun, and mTOR [39,40]. In an in vitro study, R465C disrupted recognition of its substrate (Cyclin E), resulting in substrate stabilization.

FBXW7 loss has been associated with increased cell proliferation and poor prognosis in esophageal squamous cell carcinoma [41]. In preclinical studies, FBXW7 inactivation stabilized the mTOR signaling protein and conferred sensitivity to rapamycin, an mTOR inhibitor. FBXW7 inactivation may also result in resistance to anti-tubulin chemotherapies [42]. NOTCH1 is one of the major targets of FBXW7 for degradation. Agrawal et al. [43] observed that FBXW7 mutations in HNSCC were in a hotspot known to block the degradation of active NOTCH1. In our study, one patient had a NOTCH1 E1665* mutation. As NOTCH1 can act as either an oncogene or tumor suppressor, depending on its cellular context, it may harbor both activating and inactivating mutations in cancer [44,45]. On the basis of its protein structure, E1665* is predicted to be an inactivating mutation. Genetic analysis of 74 HNSCCs revealed that 14% had mutations in NOTCH1 [46]. In contrast to acute T-cell lymphoblastic leukemia in which the activating NOTCH mutations are found in the heterodimerization or PEST (proline, glutamic acid, serine, threonine-rich) domain [47], in HNSCC, NOTCH1 mutations are largely dispersed elsewhere in the gene or produce truncated products. Therefore, NOTCH1 mutations in HNSCC are thought to represent loss-of-function changes. Activating mutations may be targeted via NOTCH inhibitors; however, there are currently no therapies available to address NOTCH1 inactivation. The BRAF V600E mutation is present in approximately 50% of metastatic melanoma cases, and vemurafenib, a BRAF inhibitor was approved by the FDA in these cases. Fifteen to 30% of patients treated with vemurafenib develop non-melanoma skin cancer; possibly due to a paradoxical activation of ras mutations in SCC that leads to accelerated growth of these lesions [7].

One tumor in our study presented a mutation in BRAF (K601E). Treatment with vemurafenib was avoided based on the history of cutaneous SCC in that patient. Most of the altered genes in our study are tumor suppressor genes: TP53, CDKN2A/B, APC, NOTCH1, FBXW7, ATM, ARID1a, ARID2. Similarly, Zhang P et al. [10] demonstrated that single nucleotide polymorphisms in tumor suppressors were more common in HPV-negative HNSCC in comparison with HPV-positive tumors. Currently, treatment strategies directed at tumor suppressor genes are limited.

To conclude, Next-generation sequencing makes it possible to detect a diversity of gene alterations in patients with advanced, recurrent HNSCC who were heavily treated prior to genetic analysis. In the present study, the application of this technique identified actionable gene alterations in 6 of 8 patients (75%). The majority of alterations were not associated with FDA-approved treatments. In 3 cases, we had 6 treatment options. Two patients showed no objective response and 3 patients were referred for clinical trials. In 2 patients, only mutations in TP53 mutation were detected. Access to early-phase clinical trials may have improved the outcome of our cohort. Further studies are needed to improve understanding of the clinical utility of next-generation sequencing in HNSCC.

References


ISSN: 2574-1241
DOI: 10.26717/BJSTR.2019.17.002991


This work is licensed under Creative Commons Attribution 4.0 License

Submission Link: https://biomedres.us/submit-manuscript.php

Assets of Publishing with us
- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

https://biomedres.us/